QGEN

Qiagen N.V. (QGEN) | Rumor.io

Qiagen

QGEN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,156

Bullish sentiment (50-day avg)64%

Price to earnings ratio22.8

Market capitalization9.3B

Earnings per share1.97

Dividend yield (TTM)0.79%

Revenue (annual)2.1B

Net income (annual)424.9M

Social

What share of all stock conversation is about QGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Jul 9

Qiagen (QGEN) is exploring strategic options, including a possible sale, after fresh interest from buyout and strategic suitors.
Reports suggest potential bidders are considering an offer of at least $50 per share, with some suitors already expressing interest in the company.
Qiagen's stock has seen a significant surge in options flows and price movement, with some analysts attributing the move to takeover buzz and potential merger and acquisition activity.

Generated by AI

Sentiment

Of the messages about QGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +42.86	76.15% +31.33
Bearish	0%	0%	0% -42.86	23.85% -31.33

Bullish· Aug 26

Commerzbank upgraded Qiagen to Buy with a price target of $66.00.
Citigroup also upgraded Qiagen to Buy, with no specific price target mentioned.
Qiagen is expected to post quarterly sales of $454.41 million, according to analysts.

Bearish· Dec 26

Qiagen has rejected a potential takeover bid, causing its stock to plummet.
The company's standalone value is less compelling without the prospect of a sale, and a premium valuation is no longer warranted.
Qiagen's strategic review has ended with no sale, and the company is now facing significant losses, potentially leading to job cuts.

Generated by AI

Topics

Of the messages about QGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	81.4%	76.51%
Technical Analysis	0%	0%	2.33%	6.68%
Earnings	0%	0%	0%	2.59%
Analysts	0%	0%	0%	10.56%
Controversies	0%	0%	16.28%	3.66%
Macro	0%	0%	0%	0%

Earnings· Aug 1

Qiagen N.V. ($QGEN) has issued earnings results, beating estimates by $0.01 EPS.
The company has updated its Q3 guidance to $0.33-0.34 EPS and FY18 guidance to $1.31-1.33 EPS.
Qiagen's earnings results beat expectations, with the company announcing $0.33 EPS.

Analysts· Oct 8

Analysts have issued mixed ratings for Qiagen N.V. (QGEN), with some downgrading the stock due to disappointing Q3 results and concerns about the China IVD and molecular testing market.
Downgrades include Underweight from Neutral at JPMorgan, Equal Weight at Barclays, and Hold at Deutsche Bank, while Bank of America maintains a Neutral rating with a $33.00 price target.
Analysts' price targets for QGEN have been reduced, including $25.00 at JPMorgan and $31.00 at Piper Jaffray, reflecting concerns about the company's performance and market trends.

Announcements· Oct 10

Qiagen N.V. is reportedly in talks to combine with Bio-Rad Laboratories in a deal worth over $10 billion.
The potential merger has caused Qiagen's shares to gap down to $42.51, with the stock trading -4.60% lower.
Oddo BHF has downgraded Qiagen's rating to Neutral from Outperform, with the stock currently trading -4.5% lower.

Generated by AI

Community

Of the messages about QGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	27.78%	52.17%
Newcomers	100%	100%	72.22%	47.83%

Regulars· Nov 7

Qiagen's Q3 2022 results exceeded expectations, with a 18% compound annual growth rate (CER) sales growth in its non-COVID product portfolio.
The company's non-GAAP earnings per share (EPS) of $0.53 beat estimates by $0.08, and revenue of $500M exceeded estimates by $17.91M.
Qiagen has raised its full-year 2022 outlook to about $2.25B, with a reaffirmed double-digit CER growth in non-COVID products, exceeding its original outlook.

Newcomers· Mar 3

The acquisition of Qiagen by Thermo Fisher Scientific is a significant deal, with a €39/share price and a 23% premium, worth an aggregate value of ~$11.5B.
The deal is expected to be highly accretive, with an 8% going-in FCF yield and growing at 7-8% annually, driven by the highly accretive and high-ROTC business of Qiagen.
The acquisition is seen as a strategic move by Thermo Fisher to expand its presence in the diagnostics and testing space, particularly in respiratory diseases, including COVID-19, and may lead to increased demand for Qiagen's products.

Generated by AI

Qiagen (NYSE:QGEN) just received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company’s rapid sepsis testing portfolio in a single automated system. Qiagen’s latest FDA clearance lands after a period of mixed trading, with the share price up 15.1% over the past 90 days but still down 5.4% year to date, while the 1-year total shareholder return of 3.2% points to modest longer term gains. Scan how Qiagen’s...

1d agoYahoo Finance

What Qiagen (QGEN)'s Expanded Sepsis Testing Portfolio Means For Shareholders

Earlier this week, QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, complementing an existing gram-positive and fungal panel and expanding its syndromic infectious disease testing menu. This clearance materially broadens QIAGEN’s coverage to 33 bloodstream pathogen targets and 28 resistance markers, reinforcing the clinical relevance of its automated...

1d agoYahoo Finance

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

GERMANTOWN, Md. & VENLO, Netherlands, September 28, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA).

2d agoYahoo! Finance Canada

Qiagen launches compact automated sample prep system

5d agoInvesting.com

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

QIAGEN NV (QGEN) launched QIAmini, a compact automated sample preparation system designed for resear

5d agofinance.yahoo.com

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

5d agoYahoo Finance

Also Discussed

Investors talking about QGEN also mention

#	Name	Attention
1	Thermo Fisher Scientific Inc.TMO	0%0
2	QuidelOrtho CorporationQDEL	0%new
3	Illumina Inc.ILMN	0%+0
4	Labcorp Holdings Inc.LH	0%0
5	Quest Diagnostics IncorporatedDGX	0%0
6	HOLX - Hologic, Inc.	——
7	Veracyte, Inc.VCYT	0%new
8	PKI - PerkinElmer, Inc.	——
9	Becton, Dickinson and CompanyBDX	0%0
10	Axalta Coating Systems Ltd.AXTA	0%0

Qiagen N.V.

Healthcare
Diagnostics & Research

Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials. Its portfolio supports workflows in areas such as genotyping, gene expression, viral and bacterial analysis, next-generation sequencing, forensic testing, and clinical decision support. The company serves laboratories, healthcare organizations, research institutions, and life science companies worldwide, making it a key supplier in molecular testing and research workflows. Qiagen N.V. is headquartered in Venlo, the Netherlands, with major operational activities in Hilden, Germany.

Website

Location

Hulsterweg 82

Venlo, MI, 5912 PL

Netherlands

Social

What share of all stock conversation is about QGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Jul 9

Qiagen (QGEN) is exploring strategic options, including a possible sale, after fresh interest from buyout and strategic suitors.
Reports suggest potential bidders are considering an offer of at least $50 per share, with some suitors already expressing interest in the company.
Qiagen's stock has seen a significant surge in options flows and price movement, with some analysts attributing the move to takeover buzz and potential merger and acquisition activity.

Generated by AI

Sentiment

Of the messages about QGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +42.86	76.15% +31.33
Bearish	0%	0%	0% -42.86	23.85% -31.33

Bullish· Aug 26

Commerzbank upgraded Qiagen to Buy with a price target of $66.00.
Citigroup also upgraded Qiagen to Buy, with no specific price target mentioned.
Qiagen is expected to post quarterly sales of $454.41 million, according to analysts.

Bearish· Dec 26

Qiagen has rejected a potential takeover bid, causing its stock to plummet.
The company's standalone value is less compelling without the prospect of a sale, and a premium valuation is no longer warranted.
Qiagen's strategic review has ended with no sale, and the company is now facing significant losses, potentially leading to job cuts.

Generated by AI

Topics

Of the messages about QGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	81.4%	76.51%
Technical Analysis	0%	0%	2.33%	6.68%
Earnings	0%	0%	0%	2.59%
Analysts	0%	0%	0%	10.56%
Controversies	0%	0%	16.28%	3.66%
Macro	0%	0%	0%	0%

Earnings· Aug 1

Qiagen N.V. ($QGEN) has issued earnings results, beating estimates by $0.01 EPS.
The company has updated its Q3 guidance to $0.33-0.34 EPS and FY18 guidance to $1.31-1.33 EPS.
Qiagen's earnings results beat expectations, with the company announcing $0.33 EPS.

Analysts· Oct 8

Analysts have issued mixed ratings for Qiagen N.V. (QGEN), with some downgrading the stock due to disappointing Q3 results and concerns about the China IVD and molecular testing market.
Downgrades include Underweight from Neutral at JPMorgan, Equal Weight at Barclays, and Hold at Deutsche Bank, while Bank of America maintains a Neutral rating with a $33.00 price target.
Analysts' price targets for QGEN have been reduced, including $25.00 at JPMorgan and $31.00 at Piper Jaffray, reflecting concerns about the company's performance and market trends.

Announcements· Oct 10

Qiagen N.V. is reportedly in talks to combine with Bio-Rad Laboratories in a deal worth over $10 billion.
The potential merger has caused Qiagen's shares to gap down to $42.51, with the stock trading -4.60% lower.
Oddo BHF has downgraded Qiagen's rating to Neutral from Outperform, with the stock currently trading -4.5% lower.

Generated by AI

Community

Of the messages about QGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	27.78%	52.17%
Newcomers	100%	100%	72.22%	47.83%

Regulars· Nov 7

Qiagen's Q3 2022 results exceeded expectations, with a 18% compound annual growth rate (CER) sales growth in its non-COVID product portfolio.
The company's non-GAAP earnings per share (EPS) of $0.53 beat estimates by $0.08, and revenue of $500M exceeded estimates by $17.91M.
Qiagen has raised its full-year 2022 outlook to about $2.25B, with a reaffirmed double-digit CER growth in non-COVID products, exceeding its original outlook.

Newcomers· Mar 3

The acquisition of Qiagen by Thermo Fisher Scientific is a significant deal, with a €39/share price and a 23% premium, worth an aggregate value of ~$11.5B.
The deal is expected to be highly accretive, with an 8% going-in FCF yield and growing at 7-8% annually, driven by the highly accretive and high-ROTC business of Qiagen.
The acquisition is seen as a strategic move by Thermo Fisher to expand its presence in the diagnostics and testing space, particularly in respiratory diseases, including COVID-19, and may lead to increased demand for Qiagen's products.

Generated by AI

Qiagen

Social

Jul 9

Bullish· Aug 26

Bearish· Dec 26

Earnings· Aug 1

Analysts· Oct 8

Announcements· Oct 10

Regulars· Nov 7

Newcomers· Mar 3

Qiagen (QGEN), What Is Behind The Fresh Attention Now?

What Qiagen (QGEN)'s Expanded Sepsis Testing Portfolio Means For Shareholders

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

Qiagen launches compact automated sample prep system

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

Also Discussed

Qiagen N.V.

Company Information

Location

Qiagen (QGEN), What Is Behind The Fresh Attention Now?

What Qiagen (QGEN)'s Expanded Sepsis Testing Portfolio Means For Shareholders

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

Qiagen launches compact automated sample prep system

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

Also Discussed

Social

Jul 9

Bullish· Aug 26

Bearish· Dec 26

Earnings· Aug 1

Analysts· Oct 8

Announcements· Oct 10

Regulars· Nov 7

Newcomers· Mar 3